Boao Lecheng pilot zone

Explore the landscape of Boao Lecheng pilot zone in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Boao Lecheng pilot zone to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

FDA Approves Viatris's RYZUMVI for Presbyopia – Phentolamine Ophthalmic Solution 0.75% Adds Age‑Related Vision Indication to Existing Mydriasis Label
CompanyDrug

FDA Approves Viatris’s RYZUMVI for Presbyopia – Phentolamine Ophthalmic Solution 0.75% Adds Age‑Related Vision Indication to Existing Mydriasis Label

Viatris Inc. (NASDAQ: VTRS) announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. RYZUMVI is already…

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

SciClone Pharmaceuticals’ Danyelza Officially Launched in China for Neuroblastoma Treatment

CompanyDrug

RareStone Group’s Pitolisant Earns Priority Review Status for Narcolepsy Treatment in China

CompanyMedical Device

Australian Scleral Lens Epicon A Approved by China’s NMPA as 10th Novel Product

CompanyDeals

Hainan Boao Lecheng Partners with Recordati on Rare Disease Drug Development

CompanyDrug

CANbridge Pharmaceuticals’ Maralixibat Approved by NMPA for Alagille Syndrome

CompanyDrug

Antengene’s Xpovio Combination Therapy Approved for Reimbursement in Australia for R/R MM

Policy / Regulatory

Hainan Boao Lecheng Introduces 319 Overseas Drugs and Devices, Reports Significant Growth

DealsPolicy / Regulatory

Hainan Province and NHSA Partner to Enhance Medical Insurance Industry with Real-World Data

Show More